Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab.
Wu M, Fulgenzi CAM, D'Alessio A, Cortellini A, Celsa C, Manfredi GF, Stefanini B, Wu YL, Huang YH, Saeed A, Pirozzi A, Pressiani T, Rimassa L, Schoenlein M, Schulze K, von Felden J, Mohamed Y, Kaseb AO, Vogel A, Roehlen N, Silletta M, Nishida N, Kudo M, Vivaldi C, Balcar L, Scheiner B, Pinter M, Singal AG, Glover J, Ulahannan S, Foerster F, Weinmann A, Galle PR, Parikh ND, Hsu WF, Parisi A, Chon HJ, Pinato DJ, Ang C.
Wu M, et al. Among authors: mohamed y.
JHEP Rep. 2024 Oct 10;7(2):101232. doi: 10.1016/j.jhepr.2024.101232. eCollection 2025 Feb.
JHEP Rep. 2024.
PMID: 39877031
Free PMC article.